Pages that link to "Q40291926"
Jump to navigation
Jump to search
The following pages link to The Efficacy and Safety of Degarelix, a GnRH Antagonist: A 12-month, Multicentre, Randomized, Maintenance Dose-finding Phase II Study in Japanese Patients with Prostate Cancer (Q40291926):
Displaying 20 items.
- Efficacy and safety of a 3-month dosing regimen of degarelix in Japanese patients with prostate cancer: a phase II maintenance-dose-finding study (Q33647728) (← links)
- Efficacy and safety of degarelix in Korean patients with prostate cancer requiring androgen deprivation therapy: Open-label multicenter phase III study (Q35827740) (← links)
- Degarelix therapy for prostate cancer in a real-world setting: experience from the German IQUO (Association for Uro-Oncological Quality Assurance) Firmagon® registry (Q35870468) (← links)
- Efficacy and safety of leuprorelin acetate 6-month depot in prostate cancer patients: a Phase III, randomized, open-label, parallel-group, comparative study in Japan (Q36299818) (← links)
- Serum testosterone levels after medical or surgical androgen deprivation: a comprehensive review of the literature (Q38114629) (← links)
- Agonists of luteinizing hormone-releasing hormone in prostate cancer (Q38132229) (← links)
- Degarelix: a review of its use in patients with prostate cancer (Q38206404) (← links)
- Bench-to-bedside development of agonists and antagonists of luteinizing hormone-releasing hormone for treatment of advanced prostate cancer (Q38289906) (← links)
- Degarelix monotherapy compared with luteinizing hormone-releasing hormone (LHRH) agonists plus anti-androgen flare protection in advanced prostate cancer: an analysis of two randomized controlled trials (Q38691255) (← links)
- Cardiovascular risk after androgen deprivation therapy for prostate cancer: an Asian perspective (Q38852165) (← links)
- Pharmacotherapeutic Targeting of G Protein-Coupled Receptors in Oncology: Examples of Approved Therapies and Emerging Concepts. (Q39236911) (← links)
- Discovery of LHRH and development of LHRH analogs for prostate cancer treatment (Q39267156) (← links)
- An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer. (Q40018470) (← links)
- A gonadotropin-releasing hormone antagonist reduces serum adrenal androgen levels in prostate cancer patients (Q41555086) (← links)
- Experience with degarelix in the treatment of prostate cancer (Q42029952) (← links)
- Landmarks in hormonal therapy for prostate cancer (Q46361234) (← links)
- Evaluation of histopathological findings at the injection site following degarelix administration (Q48061098) (← links)
- Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen-deprivation therapy (Q48858773) (← links)
- Efficacy of a neoadjuvant gonadotropin-releasing hormone antagonist plus low-dose estramustine phosphate in high-risk prostate cancer: a single-center study. (Q52905066) (← links)
- Efficacy and safety of 3-month dosing regimen of degarelix in Japanese subjects with prostate cancer: A phase III study. (Q55157282) (← links)